Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

Inclusion criteria

• Japanese subjects must have both biological parents and all four grandparents of Japanese ancestry and born in a Japanese country of origin.
• Caucasian subjects must have four Caucasian grandparents (Hispanics of white race can be considered Caucasian).
• Healthy adult male or non-pregnant non-lactating females, 18 to 75 years of age (inclusive) at the time of screening.
• Body mass index (BMI) ≥18 and ≤35 (kg/m2), inclusive, and a minimum body weight of 45 kg.

Additional inclusion criteria might apply.

Exclusion criteria

• Symptoms consistent with COVID-19 such as fever, cough, and shortness of breath within 14 days before Day 1.
• Positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening or check-in (Day -1).
• Known previous COVID-19 infection.
• Use of any prescription or over-the-counter (OTC) medication, herbal products, or dietary supplements within the 7 days or 5 half-lives, whichever is longer, prior to the first study drug administration. Use of hormonal contraception is allowed prior to and during the study.

Additional exclusion criteria might apply.